Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) with a relapsing and remitting course. It affects many individuals worldwide with deleterious effects on the quality of life.\[[@CIT1][@CIT2]\] Many medications, including anti-inflammatory drugs, corticosteroids, immunosuppressive drugs, and biological agents, are used to induce and maintain remission without curing the disease and with many side effects.\[[@CIT3][@CIT4]\]

The pathogenesis of UC is ill-understood, and seems to result from a complex interplay between susceptibility genes, environmental factors, and the immune system. Many inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-8, and others are involved.\[[@CIT5][@CIT6]\] The sources of these cytokines are the activated peripheral blood granulocytes which get mobilized first, then infiltrate the colonic mucosa and interact with lymphocytes to orchestrate the inflammatory response and initiate disease activity and/or relapse.\[[@CIT7]--[@CIT10]\] Therefore, removal of these activated granulocytes by extracorporeal cytapheresis systems, *i.e*., leukocytapheresis and granulocytapheresis may be a logical therapeutic maneuver.

The goal of this concise report is to present the available data on the efficacy, safety, and applicability of cytapheresis in patients with UC.

DEFINITION {#sec1-1}
==========

Cytapheresis is an extracorporeal removal of specific cells from the blood using special filters or columns. Due to its ability to remove white blood cells, cytapheresis has been used as a therapeutic modality in many diseases in which sensitized white cells have a pathogenic effect.\[[@CIT11][@CIT12]\] Leukocytapheresis and granulocytapheresis were mainly used in Japan, but over the last decade, they have also attracted much attention in Europe and North America.

SYSTEMS {#sec1-2}
=======

Cellsorba (Asahi Medical, Tokyo, Japan) and Adcolumn (Japan Research Laboratories, Takasaki, Japan, [Figure 1](#F0001){ref-type="fig"}) are the commonly used aphesesis systems in the current literature. The whole venous blood is perfused through an adsorption column. The blood is pumped from a peripheral vein in one arm, filtered, and returned to the body via the other arm. A total of 1800 mL blood is filtered over a period of 60 min. The device which uses an Adacolumn filter is preferred over the Cellsorba filter as it selectively removes activated granulocytes and monocytes with no significant change in the number of lymphocytes or platelets.\[[@CIT13]\]

![Schematic diagram of the leukocyte apheresis system](SJG-15-283-g001){#F0001}

CLINICAL USES {#sec1-3}
=============

The beneficial effect of Adacolumn is related to its ability to reduce numbers of granulocytes, monocytes, and inflammatory cytokine levels (TNF-α, IL-1β, IL-6, and IL-8). Additionally, the Adacolumn increases the concentration of circulating immature neutrophils and reduces their ability to secrete such pro-inflammatory cytokines.\[[@CIT14]--[@CIT16]\] Cytapheresis was first used in Japan for treating patients with leukemia in the 1980s, and is currently used in several autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, psoriasis, and IBD with varying degrees of success \[[Table 1](#T0001){ref-type="table"}\]. In UC, cytapheresis is indicated in patients with moderately severe cases (steroid-resistant or naïve cases), intractable disease (steroid-dependent), and in severe or fulminant disease.\[[@CIT17]\]

###### 

Common clinical applications[\*](#T000F1){ref-type="table-fn"} of leukocytapheresis/granulocytapheresis

  ------------------------------
  Ulcerative colitis
  Rheumatoid arthritis
  Behcet\'s disease
  Systemic lupus erythematosus
  ANCA-associated vasculitis
  Anaphylactoid purpura
  Primary biliary cirrhosis
  Crohn\'s disease
  Chronic hepatitis C
  Carcinomas
  Others
  ------------------------------

The list is not exhaustive

ADVANTAGES {#sec1-4}
==========

The principle of cytapheresis is to remove badly programmed cells instead of adding medications; this explains its relative safety. Cytapheresis does not require shunt operation, as in chronic hemodialysis, does not exacerbate anemia, nor does it influence hemodynamic parameters.\[[@CIT18][@CIT19]\] Each apheresis session lasts for 60 min and can be done in an outpatient setting. Also, it has good tolerability as each treatment course for UC consists of a single session per week for five weeks. In addition, it may improve patients\' quality of life.\[[@CIT2]\] It should be noted that cost-effectiveness has not been studied in this type of patients. Leukopheresis for IBD has not been recommended by US-FDA as first-line or even second-line treatment until now.

DISADVANTAGES {#sec1-5}
=============

Most of the adverse effects are mild and transient and are attributed to the extracorporeal circulation. These include dizziness, headache, fever, chills, nausea, vomiting, and abdominal pain. In addition, apheresis is a costly procedure compared to other therapeutic modalities. However, it is cost-effective as it reduces the number of hospital admissions, the treatment for steroid-induced side-effects, the need for the expensive biological therapies, and/or the need for surgery.\[[@CIT17]\]

EFFICACY IN UC {#sec1-6}
==============

Many studies have been conducted to evaluate the efficacy of cytapheresis in the induction of remission in patients with IBD \[[Table 2](#T0002){ref-type="table"}\].\[[@CIT19]--[@CIT42]\] Most of these studies were conducted in small numbers of patients with variable disease severity, and were open-label, uncontrolled studies; a few were randomized.\[[@CIT22][@CIT25][@CIT33]\] However, they all supported the effectiveness of cytapheresis in reducing disease activity, achieving clinical remission, and enhancing mucosal healing.

###### 

Summary of studies using cytapheresis in treating patients with ulcerative colitis

  Reference                                                    [\#](#T000F4){ref-type="table-fn"}   UC disease status                                Cases [\#](#T000F4){ref-type="table-fn"}   Apheresis protocol                                                               Side effects %   Efficacy %
  ------------------------------------------------------------ ------------------------------------ ------------------------------------------------ ------------------------------------------ -------------------------------------------------------------------------------- ---------------- ----------------------------------------
  Shimoyama *et al.* 2001                                      29                                   Refractory to conventional drugs                 53                                         Standard[\*](#T000F2){ref-type="table-fn"}                                       9                21
  Tomomasa *et al.* 2003                                       28                                   Steroid-refractory                               12                                         Once weekly for 5--10 weeks                                                      9                67
  Hanai *et al.* 2003                                          30                                   Steroid-dependent                                31 & 8                                     10-11 sessions in 11 weeks                                                       18               81-88
  Suzuki *et al.* 2004                                         31                                   Steroid-naive                                    20                                         Twice weekly for 3--5 weeks                                                      10               85
  Naganuma *et al.* 2004                                       32                                   Steroid-dependent and-refractory                 44                                         Standard[\*](#T000F2){ref-type="table-fn"}                                       5                55
  Hanai 2004[\*\*](#T000F3){ref-type="table-fn"}               33                                   Steroid-dependent                                46                                         11 sessions in 10 weeks                                                          22               83
  Yamamoto *et al.* 2004                                       34                                   Mild-to-moderate and distal                      30                                         Standard[\*](#T000F2){ref-type="table-fn"}                                       27               70
  Domenech *et al.* 2004                                       35                                   Steroid-dependent                                14                                         Standard[\*](#T000F2){ref-type="table-fn"}                                       15               62
  Kanke *et al.* 2004                                          36                                   Mild-moderate                                    60                                         10 sessions in 12 weeks                                                          18               23
  Kim *et al.* 2005                                            37                                   Refractory to conventional drugs                 27                                         Standard[\*](#T000F2){ref-type="table-fn"}                                       11               70
  Sawada *et al.* 2005                                         38                                   Moderate-severe                                  10                                         Standard[\*](#T000F2){ref-type="table-fn"}*plus 2* more sessions in 4 weeks      10               80
  Kruis *et al.* 2005                                          39                                   Steroid-dependent                                35                                         Standard[\*](#T000F2){ref-type="table-fn"}                                       3                37
  D\'Ovidio *et al.* 2006                                      40                                   Mild-moderate dependent/refractory               12                                         Standard[\*](#T000F2){ref-type="table-fn"}                                       0                25[\$](#T000F5){ref-type="table-fn"}
  Ikeda *et al.* 2006                                          26                                   Moderate-severe                                  4                                          Standard[\*](#T000F2){ref-type="table-fn"}                                       \-               50
  Sands *et al.* 2006                                          41                                   Moderate-severe                                  15                                         Standard[\*](#T000F2){ref-type="table-fn"}                                       0                33
  Okada *et al.* 2006                                          24                                   Moderate-severe                                  6                                          Once per week for 4 weeks                                                        17               83
  Kumagai *et al.* 2007                                        27                                   Recurrent (*n* = 4) and first attack (*n* = 1)   5                                          Standard[\*](#T000F2){ref-type="table-fn"} but at a rate of 50 mL/min            20               60
  Bresci *et al.* 2007                                         21                                   Acute                                            20                                         Standard[\*](#T000F2){ref-type="table-fn"}                                       10               70
  Takemoto *et al.* 2007                                       23                                   Steroid-refractory                               71                                         1--2 sessions / week for 2--10 weeks                                             \-               75[\#\#](#T000F6){ref-type="table-fn"}
  Emmrich *et al.* 2007                                        20                                   Refractory to conventional drugs                 20                                         Standard[\*](#T000F2){ref-type="table-fn"} plus 1 session/month for 6 months     \-               70
  Ljung *et al.* 2007                                          19                                   Steroid-dependent                                52                                         Standard[\*](#T000F2){ref-type="table-fn"}                                       15               48
  Aoki *et al.* 2007                                           42                                   Moderate-severe                                  22                                         2--3 sessions / week, total up to 10                                             \-               75
  Sakuraba *et al.* 2008[\*\*](#T000F3){ref-type="table-fn"}   25                                   Moderate                                         30                                         Standard[\*](#T000F2){ref-type="table-fn"} (*n* = 15) vs. Intensive (*n* = 15)                    66.7 *vs.* 80
  Hanai *et al.* 2008[\*\*](#T000F3){ref-type="table-fn"}      22                                   Moderate-severe U                                35                                         Twice weekly × 3 then once up to 11 sessions                                     14               73.4

Standard protocol = 1 session per week for five consecutive weeks, each for 60 min, with blood flow rate of 30 mL/min.

These studies are randomized controlled trial apheresis *versus* prednisolone. vs. = Versus,

= number,

= Improvement assessed endoscopically,

= in this study only 19 (27%) patients maintained remission for more than 6 months.

Interestingly, cytapheresis in pediatric patients has similar effectiveness in inducing as well as maintaining remission in steroid refractory UC as in adults. This can reduce the serious steroid-induced complications such as growth retardation, infection, and cosmetic effects.\[[@CIT26]--[@CIT28]\]

REGIMENS {#sec1-7}
========

Standard (conventional) course: One session per week for five consecutive weeks.

Intensive course: 2--3 sessions per week in the first two weeks, then once weekly. An intensive cytapheresis course induces rapid remission and is, therefore, a preferred regimen compared to the standard once-weekly course.\[[@CIT25][@CIT42]\]

POTENTIAL ROLE OF PHOTOPHERESIS {#sec1-8}
===============================

Extracorporeal photopheresis (ECP) is the *ex vivo* exposure of apheresed peripheral blood mononuclear cells to ultraviolet A light in the presence of a DNA-intercalating agent such as 8-methoxythoralin (8-MOP), and their subsequent reinfusion. ECP was used initially since the early 1980s in managing malignant and autoimmune diseases including Sezary syndrome, T-cell lymphoma, and graft-versus-host disease.\[[@CIT43]--[@CIT46]\] In ECP, exposure of circulating immune cells to UVA and 8-MOP induces immunomodulatory changes that lead to tolerance to alloreactive or autoreactive antigen-generated T-cell responses.\[[@CIT47][@CIT48]\] The potential role of ECP in combination with apheresis in patients with IBD has not been tested, and warrants further investigation.

CONCLUSIONS {#sec1-9}
===========

Cytapheresis may offer an adjuvant therapeutic option for inducing and maintaining remission in patients with chronic active UC. It is associated with a low incidence of adverse effects compared to other modalities. Well-designed placebo-controlled trials as definitive proofs of efficacy are currently underway. Also needed are studies addressing optimal treatment schemes, patients who would benefit most from this modality, when to combine it with other therapies such as immunotherapy, and the value of using ECP.

**Source of Support:** Nil

**Conflict of Interest:** None declared.
